Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (October 2026)
19 slides from Prescient Therapeutics's shareholder meeting presentation, Oct 14, 2026
Slide 1: Annual General Meeting Chair's Address
Annual General Meeting For personal use only Chair’s Address 14 October 2026 Dr James Campbell, Chair Good morning, and welcome to Prescient Therapeutics’ Annual General Meeting for 2026. A year ago, I spoke to you about PTX-100 moving from Phase 1b into Phase 2a. This year, that study became a genu
Slide 2: Chair's Address (continued)
Subject to the outcome of the Dose Optimisation Committee review and to available funding, we are also considering a further study of PTX-100 in peripheral T-cell lymphoma. For personal use only Consistent with our focus on PTX-100, investment in our cell therapy platforms, CellPryme and OmniCAR, wa
Slide 3: Ends - Contacts and About Prescient Therapeutics
- ENDS - For personal use only The Board of Prescient Therapeutics Limited has approved the release of this announcement. For more information please contact: Company enquiries Investor & Media enquiries James McDonnell Patrick Nelson CEO Reach Markets Prescient Therapeutics 1300 805 795 james.mcdon
Slide 4: CellPryme-M and Forward Looking Statements
CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing For personal use only the ability to find and penetrate tumours. CellPryme-M is a 24-h
Slide 5: AGM CEO Presentation
al use only AGM CEO Presentation James McDonnell, Chief Executive Officer 14th October 2026 ASX: PTX ptxtherapeutics.com
Slide 6: Disclaimer and Safe Harbour
Disclaimer and Safe Harbour Certain statements made in this document are forward-looking statements within the Certain statements contained in this document, including, without limitation, meaning of the safe harbor provisions of the United States Private Securities Litigation statements containing
Slide 7: Executive summary
Executive summary PTX-100: first-in-class targeted therapy disrupting the RAS pathway al use only 1 Unique and first 2 Phase 2a progressed First-in-class GGTase-1 inhibitor disrupting the 29 patients enrolled across Australia, US and Italy. RAS superfamily pathway. Understood to be the Threshold of
Slide 8: Company snapshot
Company snapshot Key metrics al use only A$0.066 A$11.8M Cash at 30 Sept 2026 plus Share price1 cap raise amount received in Oct 20263 A$75.5M A$6.0M Market capitalisation1 Raised Sept 2026 (SPP + ~1,144M Shares on issue2 shortfall)⁴ ASX: PTX | AGM 2026 1. As at 9 October 2026 2. ~1,051M pre-raise p
Slide 9: FY2026 financial review
FY2026 financial review Year ended 30 June 2026: stable cost base, strengthened balance sheet A$ million al use only A$7.0M A$3.44M 14.2 Net loss (FY25: A$7.3M, down R&D tax incentive (FY25: 11.4 4.4%) A$4.36M) 7.3 7.0 4.3 A$14.2M A$9.03M 3.4 Net assets (FY25: A$11.4M) Cash and term deposits at 30 J
Slide 10: FY2026 milestone review
FY2026 milestone review What we said we would do, and what we delivered A$6.8M SPP completed at A$0.04, plus follow- 11 Phase 2a sites active; Phase 1b study Jul 2025 Mar 2026 on placement formally closed al use only Sep 2025 7 Phase 2a sites active, 6 patients dosed Jun 2026 26 patients enrolled (1
Slide 11: Phase 2a enrolment momentum
Phase 2a enrolment momentum Recruitment accelerated through 2026 Patients enrolled (target 40 Evaluable) 20 al use only evaluable patients reached Sept 2026 (10 per arm) 29 26 12 18 sites across Australia, US and Italy; France to open 12 6 Dec 2026 first Dose Optimisation Committee review 30 Sep 25
Slide 12: Board and management
Board and management Experienced team of drug developers and deal makers with track record in blood cancers Management Team Experienced gained al use only in global companies James McDonnell Dr Rebecca Tunstall Dr Rosalind Wilson Chief Executive Officer Chief Operating Officer Chief Medical Officer
Slide 13: Our lead asset: PTX-100
Our lead asset: PTX-100 Targeted RAS-pathway therapy for cancers of unmet need • First-in-class GGTase-1 inhibitor, licensed from Yale University • Lead indication: relapsed/refractory cutaneous T-cell lymphoma al use only (r/r CTCL) ~US$1.2B • Phase 1b CTCL cohort: 43% ORR, 100% clinical benefit, n
Slide 14: Phase 1b sub-analysis of CTCL patient cohort
Phase 1b sub-analysis of CTCL patient cohort CTCL response rates, safety and duration including consideration of other therapies are key drivers to initiation of Phase 2 al use only Comparisons shown are not from head-to-head studies. Differences in trial phase, patient population, endpoints, and st
Slide 15: Progressing PTX-100 Through Phase 2a
Progressing PTX-100 Through Phase 2 Phase 2 Endpoints r/r CTCL (MF & SS) Primary endpoint: 500mg/m2 x • Objective Response Rate (ORR) al use only 2 lines of prior 20 pts Dose Secondary endpoints: systemic Phase 2a Optimisation • Skin response using mSWAT treatment Dose Optimisation Committee • Progr
Slide 16: Building value beyond CTCL
Building value beyond CTCL A staged strategy 1 Stage 1: CTCL-centric 2 Stage 2: Expansion al use only • Demonstrate efficacy and safety in Phase 2a • Bring new indications onto the platform (e.g. PTCL under evaluation) • Leverage FDA and EMA designations • Progressively address further RAS-driven ca
Slide 17: Approaching milestones – PTX-100
Approaching milestones – PTX-100 Execution will drive value (calendar years) First DOC review (20 Phase 2a enrolment evaluable patients) – complete (40 FDA Type B meeting December evaluable) on Phase 2b design al use only Q4 2026 1H 2027 2H 2027 INN name for PTX-100 1H 2027 2H 2027 France sites open
Slide 18: Summary
Summary Funded through a key value inflection point al use only 1 Unique and first 2 Phase 2a progressed First-in-class GGTase-1 inhibitor disrupting the 29 patients enrolled across Australia, US and Italy. RAS superfamily pathway. Understood to be the Threshold of 20 evaluable patients reached in o
Slide 19: Thank you
Thank you al use only October 2026 ASX: PTX ptxtherapeutics.com 15
Prescient Therapeutics — Shareholder Meeting (October 2026) on 6ix